Biomea Fusion, Inc. is a high-risk pharmaceutical company based in the United States. Specializing in irreversible small molecule drugs, they are dedicated to discovering and developing treatments for genetically defined cancers. Their flagship product, BMF-219, is an ESG-focused oral inhibitor designed to target oncogenic signaling in various cancers.